Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Martina Reberšek) .

1 - 10 / 87
Na začetekNa prejšnjo stran123456789Na naslednjo stranNa konec
1.
Gut microbiome and its role in colorectal cancer
Martina Reberšek, 2021, pregledni znanstveni članek

Povzetek: Colorectal cancer (CRC) is still one of the most common types of cancer in the world, and the gut microbiome plays an important role in its development. The microbiome is involved in the carcinogenesis, formation and progression of CRC as well as its response to different systemic therapies. The composition of bacterial strains and the influence of geography, race, sex, and diet on the composition of the microbiome serve as important information for screening, early detection and prediction of the treatment outcome of CRC. Microbiome modulation is one of the most prospective new strategies in medicine to improve the health of individuals. Therefore, future research and clinical trials on the gut microbiome in oncology as well as in the treatment of CRC patients are warranted to determine the efficacy of systemic treatments for CRC, minimize adverse effects and increase survival rates.
Objavljeno v DiRROS: 19.09.2022; Ogledov: 48; Prenosov: 22
.pdf Celotno besedilo (1,72 MB)
Gradivo ima več datotek! Več...

2.
3.
Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients : a pilot study
Nežka Hribernik, Daniel T. Huff, Andrej Studen, Katarina Zevnik, Žan Klaneček, Hamid Emamekhoo, Katja Škalič, Robert Jeraj, Martina Reberšek, 2022, izvirni znanstveni članek

Povzetek: Purpose: To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving immune-checkpoint inhibitors (ICI) imaged with 18F-FDG PET/CT. Methods: 18F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively analyzed for indication of irAE. Three target organs, most commonly affected by irAE, were considered: bowel, lung, and thyroid. Patient charts were reviewed to identify which patients experienced irAE, irAE grade, and time to irAE diagnosis. Target organs were segmented using a convolutional neural network (CNN), and novel quantitative imaging biomarkers - SUV percentiles (SUVX%) of 18F-FDG uptake within the target organs - were correlated with the clinical irAE status. Area under the receiver-operating characteristic curve (AUROC) was used to quantify irAE detection performance. Patients who did not experience irAE were used to establish normal ranges for target organ 18F-FDG uptake. Results: A total of 31% (18/58) patients experienced irAE in the three target organs: bowel (n=6), lung (n=5), and thyroid (n=9). Optimal percentiles for identifying irAE were bowel (SUV95%, AUROC=0.79), lung (SUV95%, AUROC=0.98), and thyroid (SUV75%, AUROC=0.88). Optimal cut-offs for irAE detection were bowel (SUV95%>2.7 g/mL), lung (SUV95%>1.7 g/mL), and thyroid (SUV75%>2.1 g/mL). Normal ranges (95% confidence interval) for the SUV percentiles in patients without irAE were bowel [1.74, 2.86 g/mL], lung [0.73, 1.46 g/mL], and thyroid [0.86, 1.99 g/mL]. Conclusions: Increased 18F-FDG uptake within irAE-affected organs provides predictive information about the development of irAE in MM patients receiving ICI and represents a potential quantitative imaging biomarker for irAE. Some irAE can be detected on 18F-FDG PET/CT well before clinical symptoms appear.
Ključne besede: melanoma, malignant melanoma, immune-checkpoint inhibitors, molecular imaging biomarkers
Objavljeno v DiRROS: 07.09.2022; Ogledov: 64; Prenosov: 27
.pdf Celotno besedilo (9,65 MB)

4.
Izbrane teme iz internistične onkologije za zdravnike družinske medicine, Ljubljana, junij 2022
2022, zbornik recenziranih znanstvenih prispevkov na domači konferenci

Ključne besede: internistična onkologija, družinska medicina, onkološko zdravljenje
Objavljeno v DiRROS: 30.08.2022; Ogledov: 98; Prenosov: 27
.pdf Celotno besedilo (14,13 MB)

5.
Dnevnik zdravljenja z zdravilom regorafenib
Janja Ocvirk, Martina Reberšek, Neva Volk, Tanja Mesti, Marko Boc, Marija Ignjatović, Nežka Hribernik, 2022, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Ključne besede: kemoterapija, rak debelega črevesa in danke, gastrointestinalni tumorji
Objavljeno v DiRROS: 14.07.2022; Ogledov: 115; Prenosov: 52
.pdf Celotno besedilo (2,48 MB)

6.
Adjuvantno sistemsko zdravljenje kožnega melanoma : Elektronski vir
Martina Reberšek, 2022, objavljeni znanstveni prispevek na konferenci

Ključne besede: melanom, rak kože, sistemsko zdravljenje
Objavljeno v DiRROS: 08.04.2022; Ogledov: 206; Prenosov: 75
.pdf Celotno besedilo (543,87 KB)

7.
Melanom in nemelanomski kožni raki : uredniki zbornika Marko Boc ... [et al.]
2022, zbornik strokovnih ali nerecenziranih znanstvenih prispevkov na konferenci

Ključne besede: rak kože, melanom, nemelanomski kožni raki
Objavljeno v DiRROS: 08.04.2022; Ogledov: 242; Prenosov: 143
.pdf Celotno besedilo (39,15 MB)
Gradivo ima več datotek! Več...

8.
Smernice za obravnavo bolnikov s skvamoznoceličnim karcinomom analnega kanala in kože perinealno (analnega roba)
2020, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Ključne besede: rak analnega kanala, rak analnega roba, bolniki, zdravljenje
Objavljeno v DiRROS: 18.03.2022; Ogledov: 251; Prenosov: 121
.pdf Celotno besedilo (407,06 KB)
Gradivo ima več datotek! Več...

9.
Priporočila za obravnavo bolnikov z rakom debelega črevesa in danke
2020, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Ključne besede: rak debelega črevesa, rak danke, bolniki, zdravljenje
Objavljeno v DiRROS: 18.03.2022; Ogledov: 281; Prenosov: 133
.pdf Celotno besedilo (1,30 MB)
Gradivo ima več datotek! Več...

10.
Iskanje izvedeno v 0.65 sek.
Na vrh